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Background: Although it is well recognized that fatigue is an important problem in many of 
the quiescent inflammatory bowel disease (IBD) patients, it is unknown whether the immune 
status is different in fatigued versus non-fatigued patients. In this study, we contrasted various 
characteristics of the immune system in fatigued against non-fatigued patients with IBD in 
clinical remission.
Patients and methods: Patients with IBD in clinical remission were phenotyped according 
to the Montreal classification, and the checklist individual strength-fatigue (CIS-fatigue) was 
used to assess fatigue (CIS-fatigue ≥ 35). Flow cytometry on peripheral blood samples was 
used to investigate differences in leukocyte subsets. The expression of various cytokines was 
determined in stimulated whole blood and serum samples using enzyme-linked immunosorbent 
assay. Differences between fatigued and non-fatigued patients with IBD were assessed.
Results: In total, 55 patients were included in the fatigue group (FG) and 29 patients in the 
non-fatigue group (NFG). No differences in demographic and clinical characteristics were 
observed between the groups. Flow cytometry data showed a significantly lower percentage of 
monocytes (p = 0.011) and a higher percentage of memory T-cells (p = 0.005) and neutrophils 
(p = 0.033) in the FG compared with the NFG. Whole blood stimulation showed increased 
TNF-α (p = 0.022) and IFN-γ (p = 0.047) in the FG. The median serum level was significantly 
higher for IL-12 (p < 0.001) and IL-10 (p = 0.005) and lower for IL-6 (p = 0.002) in the FG 
compared with NFG.
Conclusion: Significant differences in immune profile between fatigued and non-fatigued 
patients with IBD in clinical remission were found, which point out to a chronically active 
and Th1-skewed immune system in patients with fatigue. Whether these immune differences 
are directly involved in the fatigue complaints via immune-to-brain communication pathways 
remains to be determined. As such, further exploration of the underlying immune effects associ-
ated with fatigue is warranted to determine potential treatment options.
Keywords: inflammatory bowel disease, fatigue, leukocyte subsets, cytokines
Introduction
Patients with inflammatory bowel disease (IBD) suffer from an immune-mediated 
chronic relapsing disease. This disease significantly impairs the health-related quality 
of life of patients. Fatigue is an important factor negatively affecting the health-related 
quality of life in these patients.1–4 With >40% of patients with IBD suffering from 
fatigue, even when the disease is in remission, further understanding of the etiology 
of fatigue in IBD is warranted.1,3,5
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There is bidirectional communication between the brain 
and the immune system.
Activation of the immune system could lead to the release 
of proinflammatory cytokines that act on the brain to induce 
sickness behavior (including fatigue) or perhaps even lead to 
depression in vulnerable individuals.6 In addition, the brain 
is able to affect the immune system directly by means of 
neurotransmitters from either the sympathetic or parasym-
pathetic neurons or indirectly via the induction of hormones 
such as cortisol.7
As such, fatigue can affect the immune system and vice 
versa. If fatigue influences the immune system in IBD, it is 
well possible that stratification for pharmacological treatment 
based on fatigue status may improve clinical outcome. If 
fatigue merely reflects ongoing immune activation in patients 
with IBD, it might also implicate the potential usefulness of 
targeted therapy for IBD-related fatigue.
A variety of factors, including disease activity, female sex, 
psychological well-being, medication use, anemia and sleep 
difficulties, are known to influence the severity of fatigue in 
patients with IBD, and interestingly, many of these factors 
may in turn also affect immune parameters.3,4,8 Indeed, in 
other diseases, especially chronic fatigue syndrome (CFS), 
fatigue and immunity show important correlations.9–15 The 
mechanisms by which fatigue status is linked to the immune 
system remain largely obscure, but in view of the increasing 
evidence for the existence of a gut–brain axis, it is well pos-
sible that in IBD also, fatigue-related effect of the immune 
system may exist.16–18 This effect of the immune system was 
also proposed in fatigued multiple sclerosis and patients with 
cancer, where higher levels of proinflammatory cytokines 
were seen in fatigued patients.19,20
The observation that in patients with cancer fatigue may 
persist for years after treatment completion in otherwise 
healthy individuals is of special interest since it may reflect 
the remission situation in patients with IBD with regard to 
disease activity.21,22 In patients post cancer treatment, elevated 
levels of markers of inflammation were found in the circula-
tion (IL-1ra, sTNF-RII and IL-6R) and in peripheral blood 
mononuclear cells (PBMCs) stimulated with lipopolysac-
charide (LPS; IL-1b, IL-6 and TNF-α).23
Nevertheless, the relation between fatigue status and 
immune status in IBD remains unexplored, and thus studies 
on this aspect of IBD are urgently called for. The abovemen-
tioned considerations prompted us to investigate whether 
fatigued patients with IBD differ from non-fatigued patients 
with IBD with respect to immunity.
Patients and methods
Study design
For this study, we exploited an earlier published study cohort 
in which the effects of solution-focused therapy on fatigue 
in patients with IBD were characterized.24
The use of this cohort allowed us to include patients with 
well-characterized fatigue status. Patients from this cohort 
were asked to participate in this study.
The checklist individual strength (CIS) was used to deter-
mine whether a patient suffered from fatigue (CIS-fatigue 
subscale score ≥ 35).25
The CIS is a 20-item patient-reported validated instrument 
measuring severity of fatigue, motivation, activity level and 
concentration. The severity of fatigue, measured with the sub-
scale “fatigue”, was used as an outcome measure. Patients with 
a score of ≥ 35 on this subscale were considered to be fatigued. 
The CIS is a renewed format of the multifactorial fatigue index 
(MFI), where five questions are differently formulated and all 
other questions are the same. The CIS is standardized and uses 
a cut-off score for fatigue in contrast to the MFI.
As described in our earlier published study cohort, fecal 
calprotectin concentration was measured in the fatigued 
patients. Levels of <200 mg/g were regarded as compatible 
with disease remission.24 The Harvey–Bradshaw index (HBI) 
< 5 for Crohn’s disease or the colitis activity index (CAI) < 10 
for ulcerative colitis was used to determine clinical remission 
of the disease in the non-fatigued patients.26,27
Demographics and disease phenotype (Montreal classifi-
cation) were collected from medical records, and concomitant 
medication use was investigated using a questionnaire focus-
ing on current medication use and subjective side effects to 
medication.28
After these baseline measurements and measurements 
on blood samples, the fatigue group (FG) was enrolled in a 
clinical trial to study the effects of psychotherapy, especially 
solution-focused therapy on fatigue of which the results 
have been described.24 Consecutive patients with IBD from 
the same hospitals as the fatigue cohort, with a CIS-fatigue 
score < 35, were enrolled in the non-fatigue group (NFG) 
for this study. As in the FG, patients of the NFG were aged 
≥ 18 years, and the diagnosis of IBD was radiologically or 
endoscopically/histologically confirmed. Exclusion criteria, 
as described in the clinical trial, were equal for the FG and 
NFG.
Differences in baseline measurements between the FG 
and the NGF included laboratory values. In the NFG patients, 
only C-reactive protein (CRP) and leukocytes were measured.
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This study was conducted in accordance with the proto-
col International Conference on Harmonization Guidelines 
for Good Clinical Practice, the Declaration of Helsinki and 
local national regulations governing clinical study conduct 
and was registered at the medical ethical committee (MEC) 
of the Erasmus Medical Center (registration number: MEC-
2010-107; NL32020.078.10). The protocol was approved by 
the institutional review board (MEC) of the Erasmus Medical 
Center. All patients gave written informed consent. Patients 
were enrolled in the Netherlands from January 2010 to Janu-
ary 2011 by the principal investigator.
Blood collection and stimulation
Following blood drawing, within 24 hours serum was 
obtained using a coagulation tube and stored at -80°C until 
further analysis. Serum was collected from both fatigued 
and non-fatigued patients with IBD, and immune assays 
were conducted at the same location for all blood samples.
Heparinized whole blood samples were diluted 1:10 
with Roswell Park Memorial Institute (RPMI) 1640 (Lonza, 
Basel, Switzerland) and were stimulated with 25 mg/mL 
phytohemagglutinin (PHA; Remel, Lenexa, KS, USA) or 
100 ng/ mL LPS (Sigma-Aldrich, Zwijndrecht, the Neth-
erlands). Supernatants of the LPS- and PHA-stimulated 
cultures were obtained at 24 and 72 hours, respectively, and 
stored at -80°C until further analysis.
Leukocyte subsets analysis
After removal of erythrocytes using ery-lysis buffer, the 
heparinized whole blood samples were stained using 
antibodies against CD16 (Pacific Blue), CD14 (PerCP/
Cy5.5), CD56 (PE/Cy7) and CD62-L (Alexa Fluor 647) 
purchased from BioLegend (San Diego, CA, USA); CD3 
(AmCyan) and CD4 (APC-H7) purchased from BD Bio-
sciences (Franklin Lakes, NJ, USA); CD45RA (FITC) 
purchased from eBioscience (San Diego, CA, USA) and 
CD19 (PE) purchased from Beckman Coulter (Brea, CA, 
USA) to analyze the different leukocyte subsets using the 
FACSCanto II flow cytometer with FACSDiva software 
from BD Biosciences. The different leukocyte subsets were 
identified and counted using FlowJo software (Tree Star, 
Inc., Ashland, OR, USA).
The leukocytes were subdivided into three main popula-
tions based on forward scatter and side scatter: lymphocytes, 
granulocytes and monocytes. The different leukocyte subsets 
were subdivided into lymphocytes (T-cells, B-cells, cytotoxic 
T-cells, T-helper cells, memory T-cells, effector T-cells, naïve 
T-cells and NK-cells), monocytes (CD14+CD16+, CD14-
CD16+ and CD14+CD16-) and granulocytes (eosinophils 
and neutrophils) as shown in Table 1.
Cytokine levels
Serum and supernatant levels of IL-4, IL-5, IL-6, IL-8, IL-10, 
IL-12, TNF-α and IFN-γ were assessed using Ready-Set-Go!® 
enzyme-linked immunosorbent assay sets from eBioscience 
according to the manufacturer’s instructions and using Maxi-
Sorp 96-well plates (Nunc; Thermo Fisher Scientific, Waltham, 
MA, USA) and a model 680 microplate reader from Bio-Rad 
(Hercules, CA, USA). When levels were below the detection 
limit of 2.0, these were considered left-hand censored.
Statistical analysis
For differences in characteristics and disease phenotypes 
between the FG and NFG, χ 2 tests were used for dichotomous 
variables and t-tests for continuous variables.
Normality of laboratory parameters, leukocyte subsets 
and cytokines were determined using Shapiro–Wilk tests. 
All outcomes, except lymphocytes, granulocytes, monocytes, 
naïve T-cells and memory T-cells, were not normally distrib-
uted. Differences between the FG and NFG were analyzed 
with t-tests for normally distributed outcomes and with 
Mann–Whitney U tests for abnormally distributed outcomes. 
A number of laboratory parameters for serum cytokines were 
below the detectable range of 2.0. For these parameters, we 
performed Tobit analyses for low-censored data on the rank-
transformed variables.29 Median values, interquartile ranges 
and differences are presented in Table 1.
Tobit analyses were performed with Stata version 13.1 
(SataCorp LP, College Station, TX, USA). All other analy-
ses were performed with SPSS software for Windows, V.20 
(SPSS, Chicago, IL, USA).
Results were considered significant when two-sided 
p-values were <0.05; no correction for multiple testing was 
applied because of the exploratory nature of the study.
Results
Patient characteristics
In total, 55 fatigued patients with IBD (FG) of the earlier 
published study cohort agreed to participate in this study, 
and 29 patients in the NFG were included.
Before analyzing the differences in immune parameters, 
the demographic and clinical characteristics of the groups 
were analyzed (FG vs. NFG; Tables 2 and 3). No differences 
were observed between the two groups. With regard to remis-
sion of the disease, the NFG showed a mean CAI score of 2.3 
(standard deviation [sd] 0.6) and an HBI score of 1.2 (sd 1.1). 
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The mean calprotectin level in the FG was 66 mg/g. Based on 
these scores, both groups were in clinical remission.
Whole blood leukocytes
As a first crude indicator of a link between fatigue status and 
the immune system in patients with IBD, the composition of 
the leukocyte system was investigated using flow cytometry. 
No differences were detected in total leukocyte numbers 
(Table 1) between the groups. Within the major leukocyte 
subpopulations (lymphocytes, granulocytes and monocytes), 
a significant lower percentage of monocytes (median: FG: 
5.3, NFG: 7.2; p = 0.011) was detected in the FG compared 
with the NFG. When monocytes were further subphenotyped, 
we found a significant lower percentage of the non-classical 
CD14dim CD16+ monocytes in the FG compared with the 
NFG (median: FG: 7.9, NFG: 11.9; p = 0.017).
Within the lymphocyte subsets, no differences were 
detected; only within the CD4+ (helper) T-cell population, 
Table 1 Leukocyte subsets and cytokines
Baseline Fatigue (n = 55) Non-fatigue (n = 29) p-value
Median [Interquartile range] Median [Interquartile range]
Lymphocytes 33.2 [22.8–46.0] 35.0 [28.7–50.7] 0.188
NK-cells 2.7 [0.4–6.6] 4.7 [0.9–8.2] 0.171
B-cells 8.5 [4.7–11.2] 8.6 [4.4–12.4] 0.158
T-cells 78.3 [59.5–82.4] 77.8 [66.2–82.7] 0.963
Leukocytes 6.0 [5.1–7.6] 5.4 [4.5–7.2] 0.862
T-helper cells 64.4 [57.4–71.3] 67.6 [54.3–74.8] 0.519
Naïve T-cells 36.1 [26.5–43.0] 47.0 [29.2–58.1] 0.062
Memory T-cells* 43.7 [36.4–49.9] 33.7 [27.9–39.6] 0.005
Effector T-cells 16.5 [10.3–23.6] 12.8 [8.2–23.0] 0.263
Cytotoxic T-cells 35.6 [28.7–42.6] 32.4 [25.2–45.7] 0.527
Granulocytes 46.6 [34.2–58.6] 40.5 [28.5–52.6] 0.351
Eosinophils 3.6 [2.5–6.7] 4.9 [2.7–11.8] 0.097
Neutrophils* 77.0 [64.6–83.6] 68.8 [58.9–78.2] 0.033
Monocytes* 5.3 [3.5–7.5] 7.2 [4.7–9.1] 0.011
CD14- CD16+* 7.9 [5.7–11.5] 11.9 [7.9–15.3] 0.017
CD14+ CD16+* 3.5 [2.8–6.6] 2.6 [2.1–4.0] 0.010
CD14+ CD16- 86.9 [82.2–91.3] 84.6 [80.8–90.5] 0.361
PHA-stimulated WB
IL-5 118.1 [86.5–211.2] 85.6 [62.3–148.7] 0.078
IL-6 2452 [1629–13758] 3464 [1224–15218] 0.982
IL-8 57143 [41054–94130] 46237 [23679–85122] 0.156
IL-10 658 [326–1108] 276 [154–1133] 0.132
TNF-α* 224 [112–678] 125 [48–438] 0.022
IFN-g* 28875 [17487–51398] 9536 [2525–75476] 0.047
LPS-stimulated WB
IL-6 3115 [2394–5276] 5065 [3287–7268] 0.046
IL-8 5844 [2816–9539] 4760 [3067–10641] 0.777
IL-10 200 [107–304] 136 [96–275] 0.651
TNF-α 560 [174–1208] 206 [66–709] 0.073
Serum cytokines (% below  
detectable range in FG and NFG)
IL-4 (64%–71%) 2.0 [2.0–3.2] 2.0 [2.0–2.4] 0.570
IL-5 (19%–25%) 14.7 [3.2–54.0] 10.0 [2.0–27.6] 0.269
IL-6* (83%–42%) 2.0 [2.0–2.0] 2.3 [2.0–4.7] 0.002
IL-8 (28%–29%) 2.6 [2.0–4.8] 5.7 [2.0–50.7] 0.122
IL-10* (42%–67%) 2.2 [2.0–3.1] 2.0 [2.0–2.4] 0.005
IL-12* (4%–33%) 4.8 [3.8–9.0] 3.3 [2.0–4.4] <0.001
TNF-α (49%–4%) 49.5 [11.9–94.1] 45.1 [13.5–174.2] 0.498
IFN-g (15%–29%) 4.6 [2.8–7.3] 3.3 [2.0–10.8] 0.293
Notes: Unpaired two samples t-test for normally distributed variables (lymphocytes, granulocytes, monocytes, naïve T-cells and memory T-cells). Mann–Whitney U test for 
not normally distributed variables. Tobit test for serum cytokines with low-censored values. *p < 0.05. Lymphocytes, granulocytes and monocytes: percentage of whole blood. 
CD14+ CD16+ and CD14+ CD16- monocytes: percentage of total monocytes. T-helper cells and cytotoxic T-cells: percentage of T-cells. Naïve T-cells, memory T-cells 
and effector T-cells: percentage of T-helper cells. Eosinophils and neutrophils: percentage of granulocytes. CD14- CD16+, CD14+ CD16+ and CD14+ CD16- monocytes: 
percentage of total monocytes. Cytokine concentrations are in pg/mL.
Abbreviations: n, number of patients; PHA, phytohemagglutinin; WB, whole blood; LPS, lipopolysaccharide; FG, fatigue group; NFG, non-fatigue group.
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
87
.2
36
 o
n 
12
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical and Experimental Gastroenterology 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
87
Fatigue in patients with IBD
a significantly higher percentage of central memory CD4+ 
T cells (median: FG: 43.7, NFG: 33.7; p = 0.005) in the FG 
compared with the NFG was found. Further analysis of the 
granulocyte population showed a significantly higher percent-
age of neutrophils (median: FG: 77.0, NFG: 68.8; p = 0.033) 
in the FG compared with the NFG.
Whole blood cytokine production
In addition to the leukocyte subset analysis, we also deter-
mined the production of cytokines by the leukocytes after 
stimulation with PHA or LPS, in which PHA stimulates 
mostly lymphocytes and LPS is more prone to trigger the 
innate granulocytes and monocytes to produce cytokines 
(Table 1). PHA stimulation induced higher median cytokine 
levels in whole blood from the FG for all cytokines measured 
except for IL-6. Of these cytokines, the levels of TNF-α 
(median: FG: 224, NFG: 125; p = 0.022) and IFN-γ (median: 
FG: 28875, NFG: 9536; p = 0.047) were significantly higher 
in the FG compared with the NFG. LPS stimulation induced 
significantly higher median IL-6 levels in the NFG compared 
with the FG (median: FG: 3114, NFG: 5064; p = 0.046)
Serum cytokine levels
We also investigated the serum levels of a variety of cytokines 
(Table 1). The levels of IL-12 (median: FG: 4.8, NFG: 3.3; p 
< 0.001) and IL-10 (median: FG: 2.2, NFG: 2.0 [lower limit]; 
p = 0.005) were significantly higher in the FG serum samples, 
whereas the levels of IL-6 were significantly reduced in the 
FG serum compared with the NFG serum (median: FG: 2.0 
[lower detection limit], NFG: 2.3; p = 0.002).
Table 2 Patient characteristics
Patient characteristics Fatigue 
(n = 55)
Non-fatigue 
(n = 29)
p-value
Age in years; mean (sd) 40.1 (10.4) 40.7 (14.4) 0.861
Females, n (%) 36 (65%) 13 (45%) 0.068
Crohn’s disease, n (%) 42 (76%) 26 (90%) 0.140
Ulcerative Colitis, n (%) 13 (24%) 3 (10%)
Current medication use, n (%)
5-ASA 20 (36%) 10 (34%) 0.954
Immunosuppressives 20 (36%) 13 (45%) 0.376
Corticosteroids 10 (18%) 5 (17%) 0.971
Biologicals (anti-TNF) 13 (24%) 9 (31%) 0.406
Side effects to medication, n (%)
5-ASA 3 (5%) 1 (3%) 0.484
Immunosuppressives 11 (20%) 7 (24%) 0.402
Corticosteroids 3 (5%) 3 (10%) 0.876
Biologicals (anti-TNF) 8 (15%) 3 (10%) 0.066
Disease activity, n
CAI 14, 4 (mean) 4, 2.3 (mean) 0.805
HBI 41, 2.8 (mean) 25, 1.2 (mean) 0.035
Notes: Chi-square test for dichotomous variables and t-test for continuous 
variables. Corticosteroids: prednisone and budesonide. Immunosuppressives: 
azathioprine, methotrexate and cyclosporine.
Abbreviations: n, number of patients; sd, standard deviation; 5-ASA, 
5-aminosalicylic acid; CAI, colitis activity index; HBI, Harvey–Bradshaw index.
Table 3 Disease phenotype
Montreal classification Fatigue 
(n = 55)
Non-fatigue 
(n = 29)
p-value
Montreal classification – CD28
Mean age at diagnosis in yrs (sd) 27.4 (9.2) 24.0 (9.0) 0.135
Age at diagnosis, n (%) 
A1 4 (9.8) 7 (26.9) 0.065
A2 31 (75.6) 18 (69.2) 0.566
A3 6 (14.6) 1 (3.8) 0.159
Location
L1 4 (9.8) 3 (11.5) 0.816
L2 17 (41.5) 9 (34.6) 0.575
L3 20 (48.8) 13 (50.0) 0.922
L4 1 (2.4) 1 (3.8) 0.742
+L4 40 (2.4) 23 (11.5) 0.126
Behavior
B1 28 (68.3) 15 (57.7) 0.378
B2 6 (14.6) 6 (23.1) 0.380
B3 6 (14.6) 5 (19.2) 0.621
p 30 (26.8) 17 (34.6) 0.497
Surgery CD
Bowel resection (%) 46.3 61.5 0.225
Number of resections; mean (sd) 1 (0.9) 1.5 (1.1) 0.122
Age at first resection; mean (sd) 29.8 (9.7) 29.5 (13.1) 0.930
Stoma (%) 14.6 15.4 0.933
Rectum amputation (%) 7.3 7.7 0.955
Montreal classification – UC28
Mean age at diagnosis in yrs (sd) 29.2 (8.1) 35.7 (6.0) 0.215
Age at diagnosis, n (%)
A1 0 (0) 0 (0)
A2 13 (92.3) 2 (66.7) 0.226
A3 1 (7.7) 1 (33.3) 0.226
Location
E1 1 (7.7) 0 (0) 0.620
E2 8 (53.8) 3 (100) 0.137
E3 5 (38.5) 0 (0) 0.195
Severity
S0 7 (46.2) 0 (0) 0.137
S1 7 (53.8) 2 (66.7) 0.687
S2 0 (0) 1 (33.3) 0.032
S3 0 (0) 0 (0)
Surgery UC
Bowel resection (%) 7.1 0 0.633
Number of resections, mean 1 0 –
Age at first resection, mean 22 – –
Stoma (%) 0 0 –
Rectum amputation (%) 0 0 –
Laboratory CD and UC
CRP; median [interquartile 
range] – baseline
1.0 
[0.0–2.0]
2.0 [1.0–3.0] 0.140
Leukocytes; median 
[interquartile range] – baseline
6.0 
[5.1–7.6]
5.4 [4.5–7.2] 0.188
Notes: Chi-square test for dichotomous variables. Mann–Whitney U-test for the 
continuous variables, CRP and leukocytes. t-test for all other continuous variables.
Abbreviations: n, number of patients; CD, Crohn’s disease; yrs, years; sd, standard 
deviation; UC, ulcerative colitis; CRP, C-reactive protein.
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Discussion
A large portion of patients with IBD suffer from fatigue 
even when the disease is in clinical remission. The intricate 
bidirectional relation between the immune system and the 
brain justifies the search for possible difference in immune 
parameters in these patients.
Activation of the immune system could lead to the release 
of proinflammatory cytokines that act on the brain to induce 
sickness behavior (including fatigue) or maybe even lead to 
depression in vulnerable individuals.6 In addition, the brain 
is able to affect the immune system directly by means of 
neurotransmitters from either the sympathetic or parasym-
pathetic neurons or indirectly via the induction of hormones 
such as cortisol.7
We compared a large variety of immune parameters 
between fatigued and non-fatigued patients with IBD to 
determine whether there were parameters that were discrimi-
native between the groups.
Since we are the first to compare a large variety of immune 
parameters between patients with IBD with fatigue and 
without fatigue, we can only mirror our data to those studies 
that assessed immune parameters in patients suffering from 
fatigue in different disease settings such as cancer, CFS and 
chronic viral infections.9–15,30–36
Since viral infections are a popular proposed cause of 
CFS, it was interesting to notice that naïve CD4 cells and 
enhanced memory cells are a sign of chronic adaptive immune 
activation and have been previously reported in patients with 
chronic hepatitis C infection and were associated with cyto-
megalovirus and Helicobacter pylori titers.37–39 As such, these 
data support the idea that there may still be some ongoing 
immune activation of unknown origin involved in the fatigue 
complaints. Indeed, fatigued cancer survivors showed a 31% 
increase in circulating T lymphocytes relative to non-fatigued 
controls, particularly CD4+ T lymphocytes (41% increase) 
and CD56+ effector T lymphocytes (52% increase).
As with the T-cell changes, differences in neutrophils and 
monocytes between fatigued and non-fatigued patients could 
all be pointing toward an ongoing infection in the fatigued 
patients with IBD.
Both the significantly enhanced TNF-α and IFN-γ release 
upon stimulation with PHA are in line with observations in 
CFS patients where PBMCs instead of whole blood were 
stimulated.40 Both of them are also supportive of a Th1-
skewed immunity driving the fatigue complaints in patients 
with IBD.
With regard to the serum proinflammatory cytokine 
levels, no significant difference in the levels of TNF-α was 
observed as often reported in CFS.41,42 However, anti-TNF 
treatment could influence these results.
The enhanced IL-12 serum levels in fatigued patients with 
IBD were also in line with data previously reported on plasma 
of CFS patients compared to healthy controls.10 Although the 
reduced IL-6 levels were in contrast with this study, reduced 
IL-6 levels were reported in a recent study when moderate 
CFS patients were compared with healthy controls.10,43
The differences in immune parameters between the 
fatigued and non-fatigued patients with IBD suggest that 
there is a link between the immune system and the brain in 
IBD-associated fatigue. Whether this is a direct link cannot 
be concluded from our data.
Most of our data support the hypothesis that there is an 
ongoing low level of immune activation in patients with IBD 
who present fatigue complaints while in clinical remission. 
Because of the multifactorial origins of fatigue, there could 
be a variety of causes of the observed immune activation that 
may even differ between patients presenting similar immune 
parameters. Viral infections either acute or chronic may be 
involved in the IBD-associated fatigue.38,44 Since serology sta-
tus for different viral infections was not obtained during this 
study, we cannot rule out their possible role in at least subsets 
of the fatigued patients. Another possible cause may be the 
occurrence of microscopic relapses, at the level of the lamina 
propria, without affecting clinical disease symptoms.45 Since 
our patients were in clinical remission, no biopsies are avail-
able to rule out this possibility. Microscopic disease activity 
may enable enhanced translocation of bacteria, described as 
“leaky gut”, a phenomenon that has been associated with 
CFS as well.46,47
Since microbes are well known to influence the immune 
system, it will be interesting to include characterization of 
the microbiome in future studies focusing on fatigue in IBD 
or even consider testing therapeutic microbes for treatment 
of IBD-related fatigue.41,48
Conclusion
We show for the first time that differences in immune 
parameters are associated with fatigue symptoms in patients 
with IBD without clinically active disease. These data war-
rant further investigation into the possible causal relations 
between these parameters and the fatigue symptoms since 
this may lead to an effective resolution in part of the patients 
with IBD with fatigue.
Disclosure
The authors report no conflicts of interest in this work.
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